Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,118,100 | 2,488,200 | 2,730,000 | 3,105,900 | 2,885,600 |
| Marketable Securities | 5,487,100 | 6,524,300 | 8,114,800 | 4,636,400 | 2,809,100 |
| Receivables | 5,741,100 | 6,211,900 | 5,667,300 | 5,328,700 | 6,036,500 |
| Inventories | 3,200,800 | 3,087,300 | 2,580,500 | 2,401,900 | 1,951,300 |
| TOTAL | $18,021,900 | $18,660,900 | $19,479,200 | $15,884,100 | $14,014,900 |
| Non-Current Assets | |||||
| PPE Net | 5,120,400 | 4,599,700 | 4,146,400 | 3,763,000 | 3,482,200 |
| Investments And Advances | 10,260,600 | 8,900,100 | 5,396,500 | 6,591,800 | 6,838,000 |
| Intangibles | 1,257,400 | 1,148,600 | 1,038,600 | 915,500 | 6,700 |
| Other Non-Current Assets | 5,898,400 | 4,450,100 | 3,019,500 | 2,060,100 | 1,093,000 |
| TOTAL | $22,536,800 | $19,098,500 | $13,601,000 | $13,330,400 | $11,419,900 |
| Total Assets | $40,558,700 | $37,759,400 | $33,080,200 | $29,214,500 | $25,434,800 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 939,000 | 789,500 | 606,600 | 589,200 | 564,000 |
| Other current liabilities | 2,876,400 | 2,527,100 | 2,357,900 | 2,074,200 | 2,206,800 |
| TOTAL | $4,368,400 | $3,944,300 | $3,423,400 | $3,141,300 | $3,932,500 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,985,900 | 1,984,400 | 1,982,900 | 1,981,400 | 1,980,000 |
| Deferred Revenues | 553,000 | 627,700 | 458,900 | 477,900 | 442,000 |
| Other Non-Current Liabilities | 2,018,800 | 1,571,400 | 854,100 | 638,000 | 680,200 |
| TOTAL | $4,933,400 | $4,461,500 | $3,683,700 | $3,409,200 | $2,733,500 |
| Total Liabilities | $9,301,800 | $8,405,800 | $7,107,100 | $6,550,500 | $6,666,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 105,720 | 109,325 | 109,762 | 109,326 | 108,539 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 35,797,100 | 31,672,900 | 27,260,300 | 23,306,700 | 18,968,300 |
| Other shareholders' equity | 77,700 | -8,300 | -81,300 | -239,100 | -26,100 |
| TOTAL | $31,256,900 | $29,353,600 | $25,973,100 | $22,664,000 | $18,768,800 |
| Total Liabilities And Equity | $40,558,700 | $37,759,400 | $33,080,200 | $29,214,500 | $25,434,800 |